Table 1. Baseline characteristics of the COPD patients.
| Characteristics | N = 50 |
|---|---|
| Age, years | 69.1 ± 7.4 |
| Male/Female | 46/4 (92.0/8.0) |
| Body mass index, kg/m2 | 22.9 ± 5.5 |
| Smoking history, pack-years | 32.7 ± 23.0 |
| Active smoking | 15 (30) |
| FEV1/FVC, % | 59.8 ± 10.8 |
| FEV1, L | 1.50 ± 0.55 |
| FEV1, % predicted | 63.05 ± 21.29 |
| FVC, L | 2.45 ± 0.74 |
| FVC, % predicted | 78.20 ± 19.43 |
| Patients with exacerbation history | 7 (14.0) |
| COPD medications | |
| LABA | 2 (4.0) |
| LAMA | 19 (38.0) |
| LABA and LAMA | 6 (12.0) |
| LABA and ICS | 27 (54.0) |
| SABA | 1 (2.0) |
| SABA and SAMA | 30 (60.0) |
| Xanthine | 19 (30.0) |
| Oral prednisone | 1 (2.0) |
| Oral N-Acetylcysteine | 23 (46.0) |
| Long-term Azithromycin | 3 (6.0) |
| Comorbidities | |
| Cardiovascular disease | 25 (50.0) |
| Lung disease other than COPD | 8 (16.0) |
| Dyslipidemia | 19 (38.0) |
| Diabetes mellitus | 6 (12.0) |
| Liver disease | 6 (12.0) |
| Kidney disease | 3 (6.0) |
Data shown as mean ± SD or n (%).
kg = kilogram, m = meter, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, L = liter, LABA = Long-acting beta2-agonist, LAMA = Long-acting muscarinic antagonist, SAMA = Short-acting beta-agonist, SAMA = Short-acting muscarinic-antagonist, ICS = Inhaled corticosteroid, COPD = chronic obstructive pulmonary disease.